Slide 1: FY 2024 Results Presentation
• FY 2024 RESULTS PRESENTATION • March 24th, 2025
Slide 2: Executive Summary
ibdroot\projects\IBD-LN\fiberglass2019\643420_1\7. Marketing Materials\03 Analyst Presentation\Project Vicky_Analyst Presentation_ v55.pptx Executive Summary FY 2024 key trends and figures FY 2024 Sales at €428.5m, +1.5% excluding FX vs. FY 2023 €103.9m adjusted EBITDA in FY 2024, +9.3% vs. previous
Slide 3: FY 2024 Results At-a-Glance
ibdroot\projects\IBD-LN\fiberglass2019\643420_1\7. Marketing Materials\03 Analyst Presentation\Project Vicky_Analyst Presentation_ v55.pptx FY 2024 Results At-a-Glance Organic growth, profitability and deleverage on-track with FY2024 targets SALES Adjusted EBITDA and % Net Financial Position and Lev
Slide 4: Sales – FY 2024 vs. FY 2023
ibdroot\projects\IBD-LN\fiberglass2019\643420_1\7. Marketing Materials\03 Analyst Presentation\Project Vicky_Analyst Presentation_ v55.pptx Sales – FY 2024 vs. FY 2023 +1.5% YoY organic growth, supported by pricing SALES – FY 2023 TO FY 2024 BRIDGE €m 6.2 428.5 • +1.5% organic growth 424.7 (excl. FX
Slide 5: Sales – FY 2024 Performance by Division
ibdroot\projects\IBD-LN\fiberglass2019\643420_1\7. Marketing Materials\03 Analyst Presentation\Project Vicky_Analyst Presentation_ v55.pptx Sales – FY 2024 Performance by Division Organic growth led by Safety and Healthcare Healthcare & Life Sciences Energy & Mobility Health & Safety €m €m €m Organi
Slide 6: Adj. EBITDA – FY 2024 vs. FY 2023
ibdroot\projects\IBD-LN\fiberglass2019\643420_1\7. Marketing Materials\03 Analyst Presentation\Project Vicky_Analyst Presentation_ v55.pptx Adj. EBITDA – FY 2024 vs. FY 2023 +10.0% YoY organic growth excl. FX ADJ. EBITDA – FY 2023 TO FY 2024 BRIDGE €m 22.4% ADJUSTED EBITDA % 24.3% 190 bps of margin
Slide 7: Adj. Net Income – FY 2024 vs. FY 2023
ibdroot\projects\IBD-LN\fiberglass2019\643420_1\7. Marketing Materials\03 Analyst Presentation\Project Vicky_Analyst Presentation_ v55.pptx Adj. Net Income – FY 2024 vs. FY 2023 +13.1% YoY growth excl. FX impact, 10.4% margin (+110 bps YoY accretion) Adj. Net Income Adj. Net Income Excl. FX Gains/Lo
Slide 8: Net Financial Position – FY 2024 vs. FY 2023
ibdroot\projects\IBD-LN\fiberglass2019\643420_1\7. Marketing Materials\03 Analyst Presentation\Project Vicky_Analyst Presentation_ v55.pptx Net Financial Position – FY 2024 vs. FY 2023 Deleverage driven by operating cash-flow and NWC reduction NET FINANCIAL POSITION – FY 2023 TO FY 2024 BRIDGE €m 3.
Slide 9: FY 2025 – Strategic Focus and Guidance
ibdroot\projects\IBD-LN\fiberglass2019\643420_1\7. Marketing Materials\03 Analyst Presentation\Project Vicky_Analyst Presentation_ v55.pptx FY 2025 – Strategic Focus and Guidance Focus on M&A integration, product launch and new Healthcare platform Full integration of Whole Blood business in the newl
Slide 10: Healthcare & Life Sciences - Organizational Changes
ibdroot\projects\IBD-LN\fiberglass2019\643420_1\7. Marketing Materials\03 Analyst Presentation\Project Vicky_Analyst Presentation_ v55.pptx Healthcare & Life Sciences - Organizational Changes A new set-up to fully capture the market growth potential Previous structure New structure Healthcare & Heal
Slide 11: FY 2024 Results – Financial Statements
ibdroot\projects\IBD-LN\fiberglass2019\643420_1\7. Marketing Materials\03 Analyst Presentation\Project Vicky_Analyst Presentation_ v55.pptx FY 2024 Results – Financial Statements FY 2023 and FY 2024 P&L – Statutory Adjusted View of which FY 2023 of which FY 2024 €m FY 2023 % FY 2024 % non-recurring
Slide 12: FY 2024 Results – Financial Statements
ibdroot\projects\IBD-LN\fiberglass2019\643420_1\7. Marketing Materials\03 Analyst Presentation\Project Vicky_Analyst Presentation_ v55.pptx FY 2024 Results – Financial Statements Reclassified Balance Sheet – Dec-2023 – Dec-2024 As of As of €m 31-Dec-2023 31-Dec-2024 Net intangible fixed assets 471.7
Slide 13: FY 2024 Results – Financial Statements
ibdroot\projects\IBD-LN\fiberglass2019\643420_1\7. Marketing Materials\03 Analyst Presentation\Project Vicky_Analyst Presentation_ v55.pptx FY 2024 Results – Financial Statements Cash Flow Statement – FY 2023 – FY 2024 €m FY 2023 FY 2024 Pre-tax result 18.3 43.0 Amortisation, depreciation and writed
Slide 14: Disclaimer
ibdroot\projects\IBD-LN\fiberglass2019\643420_1\7. Marketing Materials\03 Analyst Presentation\Project Vicky_Analyst Presentation_ v55.pptx Disclaimer Pursuant to art. 154-bis, paragraph 2, of the Italian Unified Financial Act of February 24, 1998, the executive in charge of preparing the corporate